Publications by authors named "C Wolschke"

Background: Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation clearance after transplantation is unclear.

Methods: We used highly sensitive polymerase-chain-reaction technology to analyze the dynamics of driver mutations in peripheral-blood samples from 324 patients with myelofibrosis (73% with mutations, 23% with mutations, and 4% with mutations) who were undergoing transplantation after reduced-intensity conditioning.

View Article and Find Full Text PDF

Despite the development of targeted therapies in first-line AML, complete remissions (CR) cannot be achieved in 30-40%, and relapse rates remain high. In R/R AML the intensive treatment regimen of fludarabine, cytarabine, idarubicin combined with venetoclax (FLA-VIDA) showed improved remission rates compared to FLA-IDA. In this retrospective single-center analysis, we investigated the efficacy and safety of dose-reduced FLA-IDA with and without venetoclax to minimize the risk of infectious complications and excessive myelosuppression; Methods: Between 2011 and 2023, 89 R/R AML patients were treated with dose-reduced FLA-IDA (fludarabine 30 mg/m day 1-4, cytarabine 2000 mg/m day 1-4, idarubicin 10 mg/m day 1 + 4).

View Article and Find Full Text PDF

Despite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications. Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear. Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group).

View Article and Find Full Text PDF
Article Synopsis
  • - This study examined the effectiveness of three different conditioning regimens (Thiotepa-Busulfan, Sequential FLAMSA-Busulfan Fludarabine, and Treosulfan-Fludarabine) prior to allogeneic stem cell transplantation (allo-SCT) in patients with Chronic myelomonocytic leukemia (CMML) from 2006 to 2022.
  • - A total of 69 CMML patients participated, with notable variations in donor type and anti-T lymphocyte Globulin use for GVHD prophylaxis across groups.
  • - Results suggested that the Thiotepa-Busulfan group experienced better 3-year overall survival (OS) rates (80%) and progression-free survival (
View Article and Find Full Text PDF
Article Synopsis
  • The optimal TBI dose for patients with high-risk acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (SCT) is still uncertain.
  • A retrospective analysis compared outcomes of patients treated with 8 Gy and 12 Gy total body irradiation (TBI) along with fludarabine and PTCy, revealing that while both doses show similar overall and leukemia-free survival, the 12 Gy dose offers better outcomes for MRD-positive patients.
  • The study suggests that the 8 Gy TBI results in lower non-relapse mortality but a higher relapse rate compared to 12 Gy, highlighting the need for further research to confirm these results with larger MRD patient groups.
View Article and Find Full Text PDF